Edward J. Doherty
Research Subjects
Edward J. Doherty has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Stafford
John A. Paulson School of Engineering and Applied Sciences Harvard University Cambridge MA 02138 USA
28 shared publications - Ana Lako
Bristol Myers Squibb, Lawrenceville, New Jersey
28 shared publications - Anita Giobbie-Hurder
Dana-Farber Cancer Institute, Boston, MA
28 shared publications - Charles H. Yoon
Department of Surgical Oncology, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
28 shared publications - David J. Mooney
John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, USA
28 shared publications - Emily M. Thrash
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
28 shared publications
Latest Publications
- Open Access
- 30 October 2026
- Published by Springer Nature in Research Square
A Small Molecule Drug, Formoterol Fumarate, Potently Reverses Anemia
Anemia is a major societal health risk that greatly lowers quality of life in roughly a quarter of the world population1. However, current treatments are effective in only a subset of patients with hematological malignancies and disorders2,3. We have identified dynamic surface expression of β2-adrenoceptors in erythroid progenitors at various stages of differentiation. Here, we report that formoterol fumarate (FF), a highly selective β2-adrenoceptor agonist, promotes erythroid differentiation in the bone marrow and spleen to enhance hemoglobin and hematocrit levels in peripheral blood, thereby reversing anemia. FF treatment at very low doses via multiple routes of administration confers striking survival benefits in lethal hemolytic anemia. FF also boosts red blood cells in mouse models of myelodysplastic syndrome (MDS)/acute myeloid leukemia, chronic kidney disease (CKD), hemolytic stress-induced anemia, and in naïve mice at steady state. Furthermore, FF augments erythropoiesis in human stem cells derived from bone marrow aspirates of MDS patients. Mechanistically, FF promotes erythropoiesis partly via HIF-1α and associated hypoxia-responsive genes along with induction of mitochondrial biogenesis, thereby suggesting that the therapeutic relevance of FF may reflect its specific ability to induce coordinated HIF-1α and mitochondrial programs in addition to general β₂ activation. Importantly, we have developed a unique capsule formulation of FF that markedly reverses anemia when dosed orally in mice. Our study uncovers FF-driven stimulation of β2-adrenenoceptors as a new therapeutic strategy for treatment of anemia associated with MDS, CKD and hemolytic stress.
- 30 October 2026
- Published by Springer Nature in Research Square
Open AccessA Small Molecule Drug, Formoterol Fumarate, Potently Reverses Anemia
Anemia is a major societal health risk that greatly lowers quality of life in roughly a quarter of the world population1. However, current treatments are effective in only a subset of patients with hematological malignancies and disorders2,3. We have identified dynamic surface expression of β2-adrenoceptors in erythroid progenitors at various stages of differentiation. Here, we report that formoterol fumarate (FF), a highly selective β2-adrenoceptor agonist, promotes erythroid differentiation in the bone marrow and spleen to enhance hemoglobin and hematocrit levels in peripheral blood, thereby reversing anemia. FF treatment at very low doses via multiple routes of administration confers striking survival benefits in lethal hemolytic anemia. FF also boosts red blood cells in mouse models of myelodysplastic syndrome (MDS)/acute myeloid leukemia, chronic kidney disease (CKD), hemolytic stress-induced anemia, and in naïve mice at steady state. Furthermore, FF augments erythropoiesis in human stem cells derived from bone marrow aspirates of MDS patients. Mechanistically, FF promotes erythropoiesis partly via HIF-1α and associated hypoxia-responsive genes along with induction of mitochondrial biogenesis, thereby suggesting that the therapeutic relevance of FF may reflect its specific ability to induce coordinated HIF-1α and mitochondrial programs in addition to general β₂ activation. Importantly, we have developed a unique capsule formulation of FF that markedly reverses anemia when dosed orally in mice. Our study uncovers FF-driven stimulation of β2-adrenenoceptors as a new therapeutic strategy for treatment of anemia associated with MDS, CKD and hemolytic stress.
- Open Access
- 19 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data S4 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Figure S4. Vaccine characterization. A-F. Plots showing the distributions of the indicated vaccine parameters for each vaccinated patient (labelled 1 through 23). Scaffold moduli and toughness were only measured beginning at the sixth patient. Modulus refers to the Young’s modulus, which is a measure of the stiffness of the material and its resistance to deformation. Toughness describes the resistance to fracture of a material. Values in A-C represent mean and standard deviation (n = 3), while values in D-F represent single measurement (n = 1).
- 19 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S4 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Figure S4. Vaccine characterization. A-F. Plots showing the distributions of the indicated vaccine parameters for each vaccinated patient (labelled 1 through 23). Scaffold moduli and toughness were only measured beginning at the sixth patient. Modulus refers to the Young’s modulus, which is a measure of the stiffness of the material and its resistance to deformation. Toughness describes the resistance to fracture of a material. Values in A-C represent mean and standard deviation (n = 3), while values in D-F represent single measurement (n = 1).
- Open Access
- 19 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Table 5. Erythema and Induration by Vaccine Administration and Cohort
- 19 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Table 5. Erythema and Induration by Vaccine Administration and Cohort
- Open Access
- 19 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Table 6. Best Overall Response (BOR)
- 19 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Table 6. Best Overall Response (BOR)
- Open Access
- 19 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data S6 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Figure S6. The Z-score normalized expression of markers from the CyTOF panel are shown for the clusters labeled “CD163+ Monoctyes”, “NK Cells”, and “CD4 T Cells”. Markers on the Y-axis are ordered from most to least enriched.
- 19 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S6 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Figure S6. The Z-score normalized expression of markers from the CyTOF panel are shown for the clusters labeled “CD163+ Monoctyes”, “NK Cells”, and “CD4 T Cells”. Markers on the Y-axis are ordered from most to least enriched.
- Open Access
- 19 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Table 2. Adverse Events (possibly related to vaccine)
- 19 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Table 2. Adverse Events (possibly related to vaccine)
- Open Access
- 19 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data S1 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Figure S1: Patient Flow Diagram
- 19 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S1 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Figure S1: Patient Flow Diagram
- Open Access
- 19 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data S2 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Figure S2: GM-CSF Microsphere Preparation Using a Double Emulsion Process. The diagram illustrates the step-by-step method for encapsulating GM-CSF within PLGA microspheres.
- 19 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S2 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Figure S2: GM-CSF Microsphere Preparation Using a Double Emulsion Process. The diagram illustrates the step-by-step method for encapsulating GM-CSF within PLGA microspheres.
- Open Access
- 19 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 7 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Table 7. Erythema and Induration by Vaccine Administration and Cohort
- 19 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 7 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Table 7. Erythema and Induration by Vaccine Administration and Cohort
- Open Access
- 19 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Table 1. CyTOF panel profiles innate and adaptive immune populations in PBMCs.
- 19 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Table 1. CyTOF panel profiles innate and adaptive immune populations in PBMCs.